Therapeutic Solutions International (TSOI) 10-K 29 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 29, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-54554
Entity Registrant Name	Therapeutic Solutions International, Inc.
Entity Central Index Key	0001419051
Entity Tax Identification Number	45-1226465
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	701 Wild Rose Lane
Entity Address, City or Town	Elk City
Entity Address, State or Province	ID
Entity Address, Postal Zip Code	83525
City Area Code	760
Local Phone Number	295-7208
Title of 12(g) Security	Common Stock, $0.001 par value per share
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 1,296,570,604
Entity Common Stock, Shares Outstanding		2,734,250,749
Auditor Firm ID	5525
Auditor Name	Fruci & Associates II, PLLC
Auditor Location	Spokane, Washington

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 18,040	$ 94,036
Restricted cash	11,003	10,223
Accounts receivable	25,398	16,613
Inventory	42,428	39,817
Prepaid expenses and other current assets	212,352	959,307
Total current assets	309,221	1,119,996
Property and equipment, net	273,078	284,024
Right-of-use asset	8,612	34,184
Other assets	3,014,620	277,571
Total assets	3,605,531	1,715,775
Current liabilities:
Accounts payable	401,992	394,035
Accounts payable-related parties	7,209	9,791
Accrued expenses and other current liabilities	531,783	487,208
Lease liability	8,612	25,374
Notes payable, current portion	4,638	4,071
Convertible notes payable, net of discount of $175,063 and $225,800, at December 31, 2022 and 2021, respectively	65,187	79,200
Notes payable-related parties, net	988,672	965,211
Derivative liabilities	202,144	531,525
Total current liabilities	2,210,237	2,496,415
LONG TERM LIABILITIES
Notes payable, net of current portion	10,507	15,532
Lease liability, net of current portion		8,810
TOTAL LIABILITIES	2,220,744	2,520,757
Commitments and contingencies
Shareholders’ Equity (Deficit):
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 2 shares and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively
Common stock, $0.001 par value; 3,500,000,000 shares authorized; 2,617,390,830 and 2,311,123,860 shares issued and outstanding at December 31, 2022 and 2021, respectively.	2,617,392	2,311,125
Additional paid-in capital	16,334,129	10,899,139
Shares to be issued	126,324
Subscription receivable	(21,000)	(21,000)
Accumulated deficit	(17,672,058)	(13,994,246)
Total shareholders’ equity (deficit)	1,384,787	(804,982)
Total liabilities and shareholders’ equity (deficit)	$ 3,605,531	$ 1,715,775

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Debt instrument, unamortized discount, current	$ 175,063	$ 225,800
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2	0
Preferred stock, shares outstanding	2	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	3,500,000,000	3,500,000,000
Common stock, shares, issued	2,617,390,830	2,311,123,860
Common stock, shares, outstanding	2,617,390,830	2,311,123,860

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net sales	$ 206,767	$ 145,956
Cost of goods sold	79,440	42,544
Gross profit	127,327	103,412
Operating expenses:
General and administrative	491,928	138,710
Salaries, wages, and related costs	444,865	436,555
Consulting fees	432,033	264,540
Legal and professional fees	397,302	773,203
Research and development	1,441,128	794,750
Total operating expenses	3,207,256	2,407,758
Loss from operations	(3,079,929)	(2,304,346)
Other income (expense):
Loss on derivative liabilities	(131,475)	(539,006)
Change in fair value of derivative liabilities	291,123	494,501
Interest expense	(646,089)	(611,794)
Other expense	(110,642)
Total other income (expense)	(597,083)	(656,299)
LOSS BEFORE PROVISION FOR INCOME TAXES	(3,677,012)	(2,960,645)
Provision for income taxes	800	800
Net loss	$ (3,677,812)	$ (2,961,445)
Net loss per share - basic and diluted	$ 0	$ 0
Weighted average shares outstanding - basic and diluted	2,528,062,958	2,263,126,970

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Shares To Be Issued [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2020		$ 2,233,742	$ 7,041,960		$ (21,000)	$ (11,032,801)	$ (1,778,099)
Balance, shares at Dec. 31, 2020		2,233,741,391
Common stock issued for services		$ 21,000	837,900				858,900
Common stock issued for services, shares		21,000,000
Common stock issued for prepaid fees		$ 20,000	1,452,450				1,472,450
Common stock issued for prepaid fees, shares		20,000,000
Common stock issued for salaries		$ 8,342	231,457				239,799
Common stock issued for salaries, shares		8,341,723
Common stock issued for cash		$ 4,850	280,649				285,499
Common stock issued for cash, shares		4,850,075
Common stock issued for land development		$ 1,500	57,400				58,900
Common stock issued for land development, shares		1,500,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 21,691	508,044				529,735
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		21,690,671
Relief of derivative liabilities			489,279				489,279
Net loss						(2,961,445)	(2,961,445)
Balance at Dec. 31, 2021		$ 2,311,125	10,899,139		(21,000)	(13,994,246)	(804,982)
Balance, shares at Dec. 31, 2021		2,311,123,860
Common stock issued for services		$ 32,413	557,107	102,000			691,520
Common stock issued for services, shares		32,412,577
Common stock issued for prepaid fees		$ 11,000	231,320				242,320
Common stock issued for prepaid fees, shares		11,000,000
Common stock issued for salaries		$ 4,812	62,587				67,399
Common stock issued for salaries, shares		4,812,259
Common stock issued for cash		$ 44,500	400,500				445,000
Common stock issued for cash, shares		44,500,000
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 64,140	1,225,308	24,324			1,313,772
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		64,139,744
Net loss						(3,677,812)	(3,677,812)
Common stock issued for license		$ 149,402	2,958,168				3,107,570
Common stock issued for license, shares		149,402,390
Issuance of preferred stock
Issuance of preferred stock, shares	2
Balance at Dec. 31, 2022		$ 2,617,392	$ 16,334,129	$ 126,324	$ (21,000)	$ (17,672,058)	$ 1,384,787
Balance, shares at Dec. 31, 2022	2	2,617,390,830

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (3,677,812)	$ (2,961,445)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation to consultants	380,820	397,750
Stock-based compensation to related parties	310,700	461,150
Loss on derivative liabilities	131,475	539,006
Change in fair value of derivative liabilities	(291,123)	(494,501)
Amortization of prepaid stock-based compensation	951,748	480,135
Amortization of debt discount	593,463	541,612
Patent amortization	233,685	11,295
Depreciation	10,946	6,772
Changes in operating assets and liabilities:
Accounts receivable	(8,785)	(14,172)
Inventory	(2,611)	(34,418)
Prepaid expenses and other current assets	174,364	64,777
Right-of-use asset	25,572	24,792
Accounts payable	15,166	91,557
Accounts payable - related parties	(9,791)	2,581
Accrued expenses and other current liabilities	169,451	188,979
Lease liability	(25,572)	(24,792)
Net cash used in operating activities	(1,018,304)	(718,922)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(260,565)
Deposits		4,015
Net cash used in investing activities		(256,550)
Cash flows from financing activities
Payments on notes payable to related party	(2,453)	(4,799)
Proceeds from convertible notes payable	505,000	538,750
Payments on notes payable	(4,459)	(2,068)
Proceeds from sale of common stock	445,000	285,499
Net cash provided by financing activities	943,088	817,382
Net increase (decrease) in cash, cash equivalents and restricted cash	(75,216)	(158,090)
Cash, cash equivalents and restricted cash at beginning of period	104,259	262,349
Cash, cash equivalents and restricted cash at end of period	29,043	104,259
Supplemental cash flow information:
Cash paid for interest	3,173	3,312
Cash paid for income taxes	800	800
Non-cash investing and financing transactions:
Original issuance discount on convertible notes payable	39,000	33,500
Debt discount recorded in connection with derivative liability	503,726	538,750
Common stock issued in conversion of convertible notes payable and interest	1,313,772	1,019,014
Property and equipment purchased with note payable		21,671
Common stock issued for prepaid fees	242,320	1,472,450
Common stock issued for accrued salaries	67,399	239,799
Accrued interest added to principal	25,914	25,912
Common stock issued for license	3,107,570
Common stock issued for land development		58,900
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	18,040	94,036
Restricted cash	11,003	10,223
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows:	$ 29,043	$ 104,259

Organization and Business Descr

Organization and Business Description	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Description	Note 1 – Organization and Business Description Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 Business Description Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health. Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE. On Augus t the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%. In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.” The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells. Most recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production. On May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Management does not expect existing cash as of December 31, 2022 or as of March 31, 2023 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2022, the Company has incurred losses totaling $ 17.3

Basis of presentation and signi

Basis of presentation and significant accounting policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of presentation and significant accounting policies	Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries. Accounts Receivable Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. The Company recorded an allowance for doubtful accounts of $ 6,807 Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued) Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail. Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Returns. Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued) As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 202,144 531,525 Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2022 and 2021: Schedule of Change in Derivative Liability Balance, December 31, 2020 $ 437,549 Issuance of new derivative liabilities 1,077,756 Conversions (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 531,525 Issuance of new derivative liabilities 674,971 Conversions (713,229 ) Change in fair market value of derivative liabilities (291,123 ) Balance, December 31, 2022 $ 202,144 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2022 and 2021, a total of 267,136,056 95,273,690 Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $ 10,946 6,772 Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $ 233,685 11,295 Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Shipping and Handling The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within general administrative expenses. Advertising Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $ 4,132 0 Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 1,441,128 794,750 Income Taxes The Company accounts for income taxes under ASC 7”0 “Income Tax”s,” “Accounting for Income Ta”es” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued) Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 8,612

Restricted cash

Restricted cash	12 Months Ended
	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Restricted cash	Note 3 – Restricted cash Included in current assets is a $ 10,000 0.6% This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Prepaid expense and other curre

Prepaid expense and other current assets	12 Months Ended
	Dec. 31, 2022
Prepaid Expense And Other Current Assets
Prepaid expense and other current assets	Note 4 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets December 31, 2022 December 31, 2021 Prepaid consulting $ 148,550 $ 930,893 Insurance 1,141 987 Prepaid costs 62,661 27,427 Total $ 212,352 $ 959,307

Fixed assets

Fixed assets	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Fixed assets	Note 5 – Fixed assets Fixed assets consist of the following: Schedule of Fixed Assets December 31, 2022 December 31, 2021 Land $ 235,223 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 5,935 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 301,359 301,159 Accumulated depreciation (28,281 ) (17,135 ) Property and equipment, net $ 273,078 $ 284,024 Depreciation expense was $ 10,946 6,772

Other assets

Other assets	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other assets	Note 6 – Other assets Other assets consist of the following: Schedule of Other Assets December 31, 2022 December 31, 2021 Prepaid consulting $ 7,537 $ 108,673 Deposit 4,123 39,823 Licenses, net 3,002,960 129,075 Total $ 3,014,620 $ 277,571 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses December 31, 2022 December 31, 2021 Licenses $ 3,261,122 $ 153,552 Accumulated amortization (258,162 ) (24,477 ) Licenses, net $ 3,002,960 $ 129,075 Amortization expense for the years ended December 31, 2022 and 2021 was $ 233,685 24,477 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI. On February 9, 2021, the Company issued a Convertible Promissory Note (CPN) to JadiCell LLC that was never fully executed while the parties worked to finalize the agreement that resulted in an Exclusive Patent License Agreement (EPLA) being executed on September 15, 2021. Finally, a Settlement Agreement was entered into on February 23, 2022. On February 23, 2022, we issued 149,402,390 shares of common stock, valued at $ 0.0208 per share, for the EPLA, with a final value of the license being recorded at $ 3,107,570 . The Patent expires December 31, 2032 . The Exclusive Patent License to the Jadi Cell is for use under the designated areas of all applicable Lung Pathology. The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2 and will be amortized over the 10 year life of the Patent. As of March 25, 2022, we entered into a asset transfer and license agreement, which will be amortized over the life of the agreement. The agreement is until March 24, 2027 . The Company has made an initial payment of $ 200,000 . Within six months, the Company will make a second payment of $ 1.8 million. The agreement is in default and the initial paymentof $200,000 was expensed to research & development.

Convertible notes payable

Convertible notes payable	12 Months Ended
	Dec. 31, 2022
Convertible Notes Payable
Convertible notes payable	Note 7 – Convertible notes payable At various times during the year ended December 31, 2022, the Company entered into convertible promissory notes with principal amounts totaling $ 544,000 505,000 39,000 10 mature on dates ranging from January 1, 2023 to December 5, 2023 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable con’ersion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. 267,136,056 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 7 – Convertible notes payable (continued) At various times during the year ended December 31, 2021, the Company entered into convertible promissory notes with principal amounts totaling $ 572,250 538,750 33,500 10 12 mature on dates ranging from January 25, 2022 to December 15, 2022 The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to apercentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. 95,273,690 Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. For the notes issued during the year ended December 31, 2022, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $ 674,971 171,245 0.0058 0.0143 0.008 0.0272 0 148 216 0.48 4.77 one year During the year ended December 31, 2022, convertible notes principal plus their accrued interest totaling $ 774,176 68,193,798 4,054,054 39,770 0.0038 0.016 0.006 0.026 0 63 191 0.51 4.74 0.44 0.50 On December 31, 2022, the derivative liabilities on the remaining convertible notes were revalued at $ 202,144 291,123 0.0038 0.006 0 96 120 4.71 0.49 0.93 For the notes issued during the year ended December 31, 2021, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $ 1,077,756 539,006 0.0039 0.0351 0.0217 0.0540 0 197 264 0.05 0.29 one year THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 7 – Convertible notes payable (Continued) During the year ended December 31, 2021, convertible notes principal plus their accrued interest totaling $ 529,735 21,690,671 489,279 0.0136 0.035 0.022 0.057 0 125 251 0.06 0.29 0.48 0.50 On December 31, 2021, the derivative liabilities on the remaining five convertible notes were revalued at $ 531,525 494,501 0.0123 0.0127 0.029 0 165 218 0.39 0.53 0.96 The Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to the effective interest method. During the years ended December 31, 2022 and 2021, the Company amortized $ 593,463 541,612 175,063

Notes payable-related parties

Notes payable-related parties	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Notes payable-related parties	Note 8 – Notes payable-related parties Notes payable-related parties consist of: Schedule of Notes Payable Related Parties December 31, 2022 December 31, 2021 $ - $ 2,356 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10 December 31, 2019 $ - $ 2,356 One notes payable – Chief Executive Officer, unsecured, including interest at 8 10 December 31, 2019 29,090 27,577 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,448 534,544 Note payable – Chief Financial Officer, unsecured, including interest at 8 December 31, 2019 124,800 118,400 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8 10 0.005 0.004 April 20, 2019 30,334 282,334 988,672 965,211 $ 988,672 $ 965,211 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related party transactions	Note 9 – Related party transactions As of December 31, 2019 and 2018, the Company had accrued officers’ salary of $ 439,534 and $ 663,100 , respectively. One of the officers settled with the company for a note payable that is unsecured on November 8, 2019 and doesn’t accrue interest and will be paid as 0.5 % of revenues. This decreased accrued officers’ salary. The note is still outstanding as of December 31, 2022 and 2021. Payments for the years ended December 31, 2022 and 2021 was $ 97 101 In 2021, we issued 7,544,848 239,800 On June 18, 2021, we issued 2,000,000 94,600 On November 30, 2021, we issued 7,000,000 224,000 In 2022, we issued 4,812,259 67,399 On April 5, 2022, we issued 7,000,000 175,700 On September 8, 2022, we issued 4,000,000 46,400 On November 2, 2022, we issued 3,000,000 29,700 On December 30, 2022, we committed to issue 14,000,000 $84,000 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income taxes	Note 10 – Income taxes The Company is subject to United States federal and state income taxes at an approximate rate of 30 Schedule of Income tax Expense December 31, 2022 December 31, 2021 Expected income tax at statutory rate $ (709,666 ) $ (621,735 ) State tax (101,347 ) 168 Permanent differences 405,376 404,872 Other - (71,992 ) Change in valuation allowance 406,437 289,487 Provision for income taxes $ 800 $ 800 The significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2022 December 31, 2021 Net operating loss carry-forward $ 2,364,249 $ 1,957,812 Valuation allowance (2,364,249 ) (1,957,812 ) Net deferred tax asset $ - $ - The Company has Federal net operating loss carryforwards of approximately $ 9.4 7.5 7.4 5.5 5 expires beginning in fiscal 2032 As of and for the years ended December 31, 2022 and 2021, management does not believe the Company has any uncertain tax positions. Accordingly, there are no recognized tax benefits at December 31, 2022 and 2021. The Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction. The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2019. The Company currently is not under examination by any tax authority.

Equity

Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Equity	Note 11 – Equity Our authorized capital stock consists of an aggregate of 3,505,000,000 3,500,000,000 0.001 5,000,000 2,617,390,830 2 In 2021, we issued 4,850,075 285,500 In 2021, we issued 21,000,000 858,900 In 2021, we issued 8,341,723 239,799 In 2021, we issued 1,500,000 58,900 In 2021, we issued 21,690,671 1,019,014 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 11 – Equity (continued) In 2022, we issued 44,500,000 445,000 In 2022, we issued 32,412,577 691,520 In 2022, we committed to issue 3,000,000 18,000 In 2022, we issued 4,812,259 67,399 In 2022, we issued 149,402,390 3,107,570 In 2022, we issued 11,000,000 242,320 In 2022, we issued 64,139,744 1,313,772 In 2022, we committed to issue 4,054,054 15,000

Legal proceedings

Legal proceedings	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal proceedings	Note 12 – Legal proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13 – Commitments and Contingencies Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 36 April 30, 2023 During the year ended December 31, 2022 and 2021, the Company incurred rent expense of $ 25,044 22,768 The lease will expire in 2023. The weighted average discount rate used for this lease is 5 Future minimum lease payments as of December 31, 2022 are as follows: Schedule of Future Minimum Lease Payments For the year ending December 31, 2023 $ 8,612 Effective November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent events	Note 14 – Subsequent events On January 3, 2023, we issued 4,054,054 15,000 On January 3, 2023, we issued 17,000,000 0.006 On January 4, 2023, we issued 10,052,083 36,188 On January 9, 2023, we issued 4,081,632 20,000 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 14 – Subsequent events (continued) On January 9, 2023, we issued 4,000,000 0.049 On February 6, 2023, we issued 6,060,606 20,000 On February 7, 2023, we issued 11,386,719 36,438 On February 21, 2023, we issued 60,224,825 0.00216 On or about March 21, 2023, the Board of Directors of Therapeutic Solutions International, Inc. (“TSOI”), by unanimous approval, and with the unanimous approval of the Preferred A Stock holders representing at least 51% of all shareholders with the right to vote 0.0034 TSOI, which owns 15,660,000 31% 10,000,000 TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April 7, 2023 A letter will be mailed to every shareholder of record details of how to accept the Dividend Offer and a fully pre-paid return acceptance letter containing the necessary information for issuance. In addition, a Shareholder’s Rights Agreement will be enclosed, an executed copy to be returned with acceptance. Required forms and documents shall be filed with FINRA describing the identity of the parties and the Dividend Offer timely. In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2022 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Basis of presentation and sig_2

Basis of presentation and significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any subsidiaries.
Accounts Receivable	Accounts Receivable Accounts receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. The Company recorded an allowance for doubtful accounts of $ 6,807
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued) Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail. Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Returns. Shipping. Out of Stock.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0
Inventories	Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.
Derivative Liabilities	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued) As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 202,144 531,525
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the years ended December 31, 2022 and 2021: Schedule of Change in Derivative Liability Balance, December 31, 2020 $ 437,549 Issuance of new derivative liabilities 1,077,756 Conversions (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 531,525 Issuance of new derivative liabilities 674,971 Conversions (713,229 ) Change in fair market value of derivative liabilities (291,123 ) Balance, December 31, 2022 $ 202,144 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022
Use of Estimates	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.
Comprehensive Loss	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of December 31, 2022 and 2021, a total of 267,136,056 95,273,690
Depreciation and Amortization	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $ 10,946 6,772
Intangible Assets	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $ 233,685 11,295
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.
Shipping and Handling	Shipping and Handling The Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within general administrative expenses.
Advertising	Advertising Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $ 4,132 0
Research and Development	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 1,441,128 794,750
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 7”0 “Income Tax”s,” “Accounting for Income Ta”es” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Consolidated Notes to Financial Statements December 31, 2022 Note 2 – Basis of presentation and significant accounting policies (Continued)
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.
Leases	Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 8,612

Basis of presentation and sig_3

Basis of presentation and significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Change in Derivative Liability	The following is the change in derivative liability for the years ended December 31, 2022 and 2021: Schedule of Change in Derivative Liability Balance, December 31, 2020 $ 437,549 Issuance of new derivative liabilities 1,077,756 Conversions (489,279 ) Change in fair market value of derivative liabilities (494,501 ) Balance, December 31, 2021 531,525 Issuance of new derivative liabilities 674,971 Conversions (713,229 ) Change in fair market value of derivative liabilities (291,123 ) Balance, December 31, 2022 $ 202,144

Prepaid expense and other cur_2

Prepaid expense and other current assets (Tables)	12 Months Ended
	Dec. 31, 2022
Prepaid Expense And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets December 31, 2022 December 31, 2021 Prepaid consulting $ 148,550 $ 930,893 Insurance 1,141 987 Prepaid costs 62,661 27,427 Total $ 212,352 $ 959,307

Fixed assets (Tables)

Fixed assets (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following: Schedule of Fixed Assets December 31, 2022 December 31, 2021 Land $ 235,223 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 5,935 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 301,359 301,159 Accumulated depreciation (28,281 ) (17,135 ) Property and equipment, net $ 273,078 $ 284,024

Other assets (Tables)

Other assets (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets consist of the following: Schedule of Other Assets December 31, 2022 December 31, 2021 Prepaid consulting $ 7,537 $ 108,673 Deposit 4,123 39,823 Licenses, net 3,002,960 129,075 Total $ 3,014,620 $ 277,571
Schedule of Net Licenses	Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses December 31, 2022 December 31, 2021 Licenses $ 3,261,122 $ 153,552 Accumulated amortization (258,162 ) (24,477 ) Licenses, net $ 3,002,960 $ 129,075

Notes payable-related parties (

Notes payable-related parties (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Notes Payable Related Parties	Notes payable-related parties consist of: Schedule of Notes Payable Related Parties December 31, 2022 December 31, 2021 $ - $ 2,356 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10 December 31, 2019 $ - $ 2,356 One notes payable – Chief Executive Officer, unsecured, including interest at 8 10 December 31, 2019 29,090 27,577 One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues 534,448 534,544 Note payable – Chief Financial Officer, unsecured, including interest at 8 December 31, 2019 124,800 118,400 Three notes payable – Business Advisory Board Member, unsecured, including interest at 8 10 0.005 0.004 April 20, 2019 30,334 282,334 988,672 965,211 $ 988,672 $ 965,211

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Income tax Expense	Schedule of Income tax Expense December 31, 2022 December 31, 2021 Expected income tax at statutory rate $ (709,666 ) $ (621,735 ) State tax (101,347 ) 168 Permanent differences 405,376 404,872 Other - (71,992 ) Change in valuation allowance 406,437 289,487 Provision for income taxes $ 800 $ 800
Schedule of Deferred Tax Assets and Liabilities	The significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows: Schedule of Deferred Tax Assets and Liabilities December 31, 2022 December 31, 2021 Net operating loss carry-forward $ 2,364,249 $ 1,957,812 Valuation allowance (2,364,249 ) (1,957,812 ) Net deferred tax asset $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of December 31, 2022 are as follows: Schedule of Future Minimum Lease Payments For the year ending December 31, 2023 $ 8,612

Organization and Business Des_2

Organization and Business Description (Details Narrative) - USD ($) $ in Millions		12 Months Ended
	Aug. 04, 2021	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity incorporation date		Aug. 06, 2007
Unusual or infrequent item, description	the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.
Net loss		$ 17.3

Schedule of Change in Derivativ

Schedule of Change in Derivative Liability (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Beginning Balance	$ 531,525	$ 437,549
Issuance of new derivative liabilities	674,971	1,077,756
Conversions	(713,229)	(489,279)
Change in fair market value of derivative liabilities	(291,123)	(494,501)
Ending Balance	$ 202,144	$ 531,525

Basis of presentation and sig_4

Basis of presentation and significant accounting policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Allowance for doubtful accounts	$ 6,807	$ 6,807
Payments description	Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
Cash, FDIC insured amount	$ 0	0
Derivative liabilities	$ 202,144	$ 531,525
Antidilutive securities excluded from computation of earnings per share	267,136,056	95,273,690
Depreciation expense	$ 10,946	$ 6,772
Amortization expense	233,685	11,295
Advertising expense	4,132	0
Research and development expense	1,441,128	794,750
Lease liability	8,612
Right-of-use asset	8,612	$ 34,184
Maximum [Member]
Property, Plant and Equipment [Line Items]
Cash, FDIC insured amount	$ 250,000

Restricted cash (Details Narrat

Restricted cash (Details Narrative)	12 Months Ended
	Dec. 31, 2022 USD ($)
Cash and Cash Equivalents [Abstract]
Restricted cash and non-cash equivalents	$ 10,000
Annual interest rate	0.60%
Restricted cash description	This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expense And Other Current Assets
Prepaid consulting	$ 148,550	$ 930,893
Insurance	1,141	987
Prepaid costs	62,661	27,427
Total	$ 212,352	$ 959,307

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total	$ 301,359	$ 301,159
Accumulated depreciation	(28,281)	(17,135)
Property and equipment, net	273,078	284,024
Land [Member]
Property, Plant and Equipment [Line Items]
Total	235,223	235,223
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total	50,514	50,514
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	6,135	5,935
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	7,912	7,912
Shipping and Other Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 1,575	$ 1,575

Fixed assets (Details Narrative

Fixed assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 10,946	$ 6,772

Schedule of Other Assets (Detai

Schedule of Other Assets (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid consulting	$ 7,537	$ 108,673
Deposit	4,123	39,823
Licenses, net	3,002,960	129,075
Total	$ 3,014,620	$ 277,571

Schedule of Net Licenses (Detai

Schedule of Net Licenses (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Licenses	$ 3,261,122	$ 153,552
Accumulated amortization	(258,162)	(24,477)
Licenses, net	$ 3,002,960	$ 129,075

Other assets (Details Narrative

Other assets (Details Narrative) - USD ($)			12 Months Ended
	Mar. 25, 2022	Feb. 23, 2022	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortization expenses			$ 233,685	$ 24,477
Stock Issued During Period, Value, New Issues			$ 445,000	$ 285,499
Exclusive patent license agreement [Member] | Convertible Promissory Note [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues		149,402,390
Share Price		$ 0.0208
Stock Issued During Period, Value, New Issues		$ 3,107,570
[custom:PatentExpiresAgreementDate]		Dec. 31, 2032
Finite-Lived Intangible Assets, Remaining Amortization Period		10 years
Assets Transfer and License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortized life of agreement	Mar. 24, 2027
Assets Transfer and License Agreement [Member] | Initial Payment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to Acquire Intangible Assets	$ 200,000
Assets Transfer and License Agreement [Member] | Second Payment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to Acquire Intangible Assets	$ 1,800,000

Convertible notes payable (Deta

Convertible notes payable (Details Narrative)	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Debt Instrument [Line Items]
Debt original issuance discount	$ 505,000	$ 538,750
Loss on derivative liability	131,475	539,006
Derivative liabilities	202,144	531,525
Gain loss on derivative liabilities	291,123	494,501
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt discount	175,063
Interest expenses	593,463	541,612
Derivative [Member]
Debt Instrument [Line Items]
Derivative issuance liability	674,971	1,077,756
Loss on derivative liability	$ 171,245	$ 539,006
Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0	0
Derivative [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term	1 year	1 year
Minimum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0058	0.0039
Minimum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.008	0.0217
Minimum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	148	197
Minimum [Member] | Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.48	0.05
Maximum [Member] | Derivative [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0143	0.0351
Maximum [Member] | Derivative [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0272	0.0540
Maximum [Member] | Derivative [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	216	264
Maximum [Member] | Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.77	0.29
Convertible Promissory Note [Member]
Debt Instrument [Line Items]
Debt principal amount	$ 544,000	$ 572,250
Debt original issuance discount	505,000	538,750
Debt discount	$ 39,000	$ 33,500
Interest rate percentage	10%
Debt maturity date description	mature on dates ranging from January 1, 2023 to December 5, 2023	mature on dates ranging from January 25, 2022 to December 15, 2022
Debt conversion description	The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable con’ersion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.	The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to apercentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.
Common shares reserve | shares	267,136,056	95,273,690
Convertible Promissory Note [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest rate percentage		10%
Convertible Promissory Note [Member] | Maximum [Member]
Debt Instrument [Line Items]
Interest rate percentage		12%
Convertible Notes [Member]
Debt Instrument [Line Items]
Loss on derivative liability	$ 39,770
Debt conversion of convertible shares, value	$ 774,176	$ 529,735
Debt conversion of convertible shares | shares	68,193,798	21,690,671
Common stock, subscribed and issued | shares	4,054,054
Additional paid in capital on convertible debt features		$ 489,279
Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input		0
Convertible Notes [Member] | Minimum [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0038	0.0136
Convertible Notes [Member] | Minimum [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.006	0.022
Convertible Notes [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	63	125
Convertible Notes [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0.51	0.06
Convertible Notes [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term	5 months 8 days	5 months 23 days
Convertible Notes [Member] | Maximum [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.016	0.035
Convertible Notes [Member] | Maximum [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.026	0.057
Convertible Notes [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	191	251
Convertible Notes [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.74	0.29
Convertible Notes [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term	6 months	6 months
Convertible Notes Payable [Member] | Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0
Remaining Convertible Notes [Member]
Debt Instrument [Line Items]
Derivative liabilities	$ 202,144	$ 531,525
Gain loss on derivative liabilities	$ 291,123	$ 494,501
Remaining Convertible Notes [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.006	0.029
Remaining Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0	0
Remaining Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.71	0.39
Remaining Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0038
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares		0.0123
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	96	165
Remaining Convertible Notes [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term	5 months 26 days	6 months 10 days
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Conversion Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares		0.0127
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	120	218
Remaining Convertible Notes [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term	11 months 4 days	11 months 15 days

Schedule of Notes Payable Relat

Schedule of Notes Payable Related Parties (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Notes payable related party, current	$ 988,672	$ 965,211
Notes payable related party, non-current	988,672	965,211
Notes Payable One [Member]
Short-Term Debt [Line Items]
Notes payable related party, current		2,356
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Notes payable related party, current	29,090	27,577
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Notes payable related party, current	534,448	534,544
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Notes payable related party, current	124,800	118,400
Notes Payable Five [Membe]
Short-Term Debt [Line Items]
Notes payable related party, current	$ 30,334	$ 282,334

Schedule of Notes Payable Rel_2

Schedule of Notes Payable Related Parties (Details) (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Scientific Advisory Board [Member] | Notes Payable One [Member]
Short-Term Debt [Line Items]
Debt interest percentage	10%	10%
Debt maturity date	Dec. 31, 2019	Dec. 31, 2019
Chief Executive Officer [Member] | Notes Payable Two [Member]
Short-Term Debt [Line Items]
Debt maturity date	Dec. 31, 2019	Dec. 31, 2019
Chief Executive Officer [Member] | Notes Payable Two [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt interest percentage	8%	8%
Chief Executive Officer [Member] | Notes Payable Two [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt interest percentage	10%	10%
Chief Financial Officer [Member] | Notes Payable Four [Member]
Short-Term Debt [Line Items]
Debt interest percentage	8%	8%
Debt maturity date	Dec. 31, 2019	Dec. 31, 2019
Business Advisory Board [Member] | Notes Payable Five [Membe]
Short-Term Debt [Line Items]
Debt maturity date	Apr. 20, 2019	Apr. 20, 2019
Business Advisory Board [Member] | Notes Payable Five [Membe] | Minimum [Member]
Short-Term Debt [Line Items]
Debt interest percentage	8%	8%
Share price	$ 0.004	$ 0.004
Business Advisory Board [Member] | Notes Payable Five [Membe] | Maximum [Member]
Short-Term Debt [Line Items]
Debt interest percentage	10%	10%
Share price	$ 0.005	$ 0.005

Related party transactions (Det

Related party transactions (Details Narrative) - USD ($)							12 Months Ended
	Dec. 30, 2022	Nov. 02, 2022	Sep. 08, 2022	Apr. 05, 2022	Nov. 30, 2021	Jun. 18, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2018
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Related Party Transaction, Rate							0.50%
Payments							$ 97	$ 101
Number of common stock issued, value							$ 445,000	$ 285,499
Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Accrued Salaries, Current									$ 439,534	$ 663,100
One Officers [Member] | Restricted Stock [Member] | Accrued Salaries [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of common stock issued							4,812,259	7,544,848
Number of common stock issued, value							$ 67,399	$ 239,800
One Officer and One Director [Member] | Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of common stock issued			4,000,000			2,000,000
Number of common stock issued, value			$ 46,400			$ 94,600
Four Officer and One Director [Member] | Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of common stock issued	14,000,000			7,000,000	7,000,000
Number of common stock issued, value	$ 84,000			$ 175,700	$ 224,000
Four Officer One Director [Member] | Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of common stock issued		3,000,000
Number of common stock issued, value		$ 29,700

Schedule of Income tax Expense

Schedule of Income tax Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Expected income tax at statutory rate	$ (709,666)	$ (621,735)
State tax	(101,347)	168
Permanent differences	405,376	404,872
Other		(71,992)
Change in valuation allowance	406,437	289,487
Provision for income taxes	$ 800	$ 800

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carry-forward	$ 2,364,249	$ 1,957,812
Valuation allowance	(2,364,249)	(1,957,812)
Net deferred tax asset

Income taxes (Details Narrative

Income taxes (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal and state income taxes rate	30%
Federal net operating loss carryfowards	$ 9.4	$ 7.5
State net operating loss carryfowards	7.4	$ 5.5
Net operating loss carryforwards are available to offset taxable income	$ 5
Net operating loss carryforwards, expiration, description	expires beginning in fiscal 2032

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)							12 Months Ended
	Mar. 21, 2023	Feb. 21, 2023	Feb. 07, 2023	Feb. 06, 2023	Jan. 04, 2023	Jan. 03, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Aggregate authorized capital							3,505,000,000
Common stock, shares authorized							3,500,000,000	3,500,000,000
Common stock, par value							$ 0.001	$ 0.001
Preferred Stock, Shares Authorized							5,000,000	5,000,000
Common stock, shares outstanding							2,617,390,830	2,311,123,860
Preferred stock, shares outstanding							2	0
Preferred stock, shares issued							2	0
Common stock issued for cash							$ 445,000	$ 285,499
Common stock issued for cash, shares							1,313,772	529,735
Common stock issued for cash, shares							$ 691,520	$ 858,900
Prepaid Fees [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash, shares							11,000,000
Common stock issued for cash							$ 242,320
Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash, shares	15,660,000
Convertible Notes Payable [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of convertible notes							64,139,744	21,690,671
Common stock issued for cash, shares							$ 1,313,772	$ 1,019,014
Convertible Notes Payable [Member] | Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion of convertible notes			11,386,719	6,060,606	10,052,083	4,054,054
Common stock issued for cash, shares			$ 36,438	$ 20,000	$ 36,188	$ 15,000
Land Development [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash, shares								1,500,000
Common stock issued for cash								$ 58,900
Salaries [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash, shares							4,812,259	8,341,723
Common stock issued for cash							$ 67,399	$ 239,799
Consulting Services [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash, shares							32,412,577	21,000,000
Common stock issued for cash							$ 691,520	$ 858,900
Consulting Services [Member] | Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash						18,000
Common stock issued for cash, shares						$ 3,000,000
License [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash, shares							149,402,390
Common stock issued for cash							$ 3,107,570
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash, shares							44,500,000	4,850,075
Common stock issued for cash							$ 445,000	$ 285,500
Private Placement [Member] | Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for cash, shares		60,224,825

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details)	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023	$ 8,612

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	12 Months Ended
	Dec. 31, 2022 USD ($) ft²	Dec. 31, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Area of land | ft²	1,700
Lease contract term	36 months
Lease expiration date	Apr. 30, 2023
Payment for rent | $	$ 25,044	$ 22,768
Operating lease discount rate	5%

Subsequent events (Details Narr

Subsequent events (Details Narrative)								12 Months Ended
	Mar. 21, 2023 shares	Feb. 21, 2023 $ / shares shares	Feb. 07, 2023 USD ($) shares	Feb. 06, 2023 USD ($) shares	Jan. 09, 2023 USD ($) $ / shares shares	Jan. 04, 2023 USD ($) shares	Jan. 03, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares
Subsequent Event [Line Items]
Conversion of common stock | $								$ 1,313,772	$ 529,735
Common stock issued for cash | $								$ 445,000	$ 285,499
Private Placement [Member]
Subsequent Event [Line Items]
Common stock issued for cash, shares								44,500,000	4,850,075
Common stock issued for cash | $								$ 445,000	$ 285,500
Subsequent Event [Member]
Subsequent Event [Line Items]
Shares issued for consulting services					4,000,000		17,000,000
Shares issued price per share | $ / shares					$ 0.049		$ 0.006
Common stock issued for cash, shares	15,660,000
Subsequent Event [Member] | Campbell Neurosciences Inc [Member]
Subsequent Event [Line Items]
Dividend conversion rate	0.0034
Common stock shares percentage	31%
Common stock divident	10,000,000
Dividend, description	TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April 7, 2023 (“Dividend Offer”) on April 8, 2023 (“Dividend Offer Date”). The Dividend Offer will remain open for Ninety (90) days from the Dividend Offer Date
Dividend offer date	Apr. 07, 2023
Subsequent Event [Member] | Preferred Class A [Member] | Director [Member]
Subsequent Event [Line Items]
Right of voting	Preferred A Stock holders representing at least 51% of all shareholders with the right to vote
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Shares issued price per share | $ / shares		$ 0.00216
Common stock issued for cash, shares		60,224,825
Subsequent Event [Member] | Accrued Salaries [Member]
Subsequent Event [Line Items]
Common stock issued for cash, shares					4,081,632
Common stock issued for cash | $					$ 20,000
Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares								64,139,744	21,690,671
Conversion of common stock | $								$ 1,313,772	$ 1,019,014
Convertible Notes Payable [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Conversion of common stock, shares			11,386,719	6,060,606		10,052,083	4,054,054
Conversion of common stock | $			$ 36,438	$ 20,000		$ 36,188	$ 15,000